An overview of the progress in the treatment of multiple myeloma

Expert Review of Hematology

Volumn 7, Issue 1, 2014, Pages 5-7

  Kyle, Robert A ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

historical features; melphalan; multiple myeloma; novel agents; stem cell transplantation

Indexed keywords

BORTEZOMIB; CAMPHOR; CARFILZOMIB; CYCLOPHOSPHAMIDE; KINESIN; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PLACEBO; POMALIDOMIDE; PREDNISONE; SALINOSPORAMIDE A; SERUM GLOBULIN; THALIDOMIDE; UBIQUITIN; URETHAN;

ALLOGENIC BONE MARROW TRANSPLANTATION; BEHCET DISEASE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE DURATION; DRUG EFFECT; DRUG TREATMENT FAILURE; ERYTHEMA NODOSUM LEPROSUM; HEMATOCRIT; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANGIOGENESIS INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 84893269542     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.870030     Document Type: Review

References (21)

1. Solly S. Remarks on the pathology of mollities ossium with cases. Med. Chir. Trans. 27, 435-461 (1844).
2. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med. Chir. Trans. 33, 211-232 (1850).
3. Alwall N. Urethane and stilbamidine in multiple myeloma: report on two cases. Lancet 2, 388-389 (1947).
4. Holland JR, Hosley H, Scharlau C et al. A controlled trial of urethane treatment in multiple myeloma. Blood 27(3), 328-342 (1966).
5. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. [Clinical experiences with sarcolysin in neoplastic diseases]. Ann. NY Acad. Sci. 68(3), 1128-1132 (1958).
6. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother. Rep. 21, 87-99 (1962).
7. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother. Rep. 16, 257-259 (1962).
8. Salmon SE, Shadduck RK, Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother. Rep. 51(3), 179-187 (1967).
9. McIntyre OR, Pajak TF, Kyle RA, Cornwell GG 3rd, Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med. Pediatr. Oncol. 13(5), 239-243 (1985).
10. Hoogstraten B, Sheehe PR, Cuttner J et al. Melphalan in multiple myeloma. Blood 30(1), 74-83 (1967).
11. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208(9), 1680-1685 (1969).
12. Harley JB, Ramanan SV, Kim I et al. The cyclic use of multiple alkylating agents in multiple myeloma. WV Med. J. 68(1), 1-3 (1972).
13. Group MTC. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from randomized trials. Myeloma Trialists' Collaborative Group. J.Clin. Oncol. 16(12), 3832-3842 (1998).
14. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol. 68(3), 215-223 (1982).
15. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2(8354), 822-824 (1983).
16. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70(3), 869-872 (1987).
17. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999); Erratum in: N. Engl. J. Med. 342(5), 364 (2000).
18. Lenz W. Thalidomide and congenital abnormalities Lancet 1, 45 (1962).
19. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61(7), 3071-3076 (2001).
20. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma [see comment]. N. Engl. J. Med. 348(26), 2609-2617 (2003).
21. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13), 4050-4053 (2005).